Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
(World News Science)

The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019 LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The safety assessments in the single- and multiple-ascending dose trials in healthy volunteers showed that the drug was well tolerated over the dose ranges tested, which include the doses expected to be evaluated in Phase 2 testing. Importantly, key blood and urine markers of kidney function did...